 |
|
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
P. Michael Ho, MD, PhD;
Thomas M. Maddox, MD, MSc;
Li Wang, MS;
Stephan D. Fihn, MD, MPH;
Robert L. Jesse, MD, PhD;
Eric D. Peterson, MD, MPH;
John S. Rumsfeld, MD, PhD
JAMA. 2009;301(9):937-944.
Context Prior mechanistic studies reported that omeprazole decreases the platelet inhibitory effects of clopidogrel, yet the clinical significance of these findings is not clear.
Objective To assess outcomes of patients taking clopidogrel with or without a proton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS).
Design, Setting, and Patients Retrospective cohort study of 8205 patients with ACS taking clopidogrel after discharge from 127 Veterans Affairs hospitals between October 1, 2003, and January 31, 2006. Vital status information was available for all patients through September 30, 2006.
Main Outcome Measures All-cause mortality or rehospitalization for ACS.
Results Of 8205 patients taking clopidogrel after discharge, 63.9% (n = 5244) were prescribed PPI at discharge, during follow-up, or both and 36.1% (n = 2961) were not prescribed PPI. Death or rehospitalization for ACS occurred in 20.8% (n = 615) of patients taking clopidogrel without PPI and 29.8% (n = 1561) of patients taking clopidogrel plus PPI. In multivariable analyses, use of clopidogrel plus PPI was associated with an increased risk of death or rehospitalization for ACS compared with use of clopidogrel without PPI (adjusted odds ratio [AOR], 1.25; 95% confidence interval [CI], 1.11-1.41). Among patients taking clopidogrel after hospital discharge and prescribed PPI at any point during follow-up (n = 5244), periods of use of clopidogrel plus PPI (compared with periods of use of clopidogrel without PPI) were associated with a higher risk of death or rehospitalization for ACS (adjusted hazard ratio, 1.27; 95% CI, 1.10-1.46). In analyses of secondary outcomes, patients taking clopidogrel plus PPI had a higher risk of hospitalizations for recurrent ACS compared with patients taking clopidogrel without PPI (14.6% vs 6.9%; AOR, 1.86 [95% CI, 1.57-2.20]) and revascularization procedures (15.5% vs 11.9%; AOR, 1.49 [95% CI, 1.30-1.71]), but not for all-cause mortality (19.9% vs 16.6%; AOR, 0.91 [95% CI, 0.80-1.05]). The association between use of clopidogrel plus PPI and increased risk of adverse outcomes also was consistent using a nested case-control study design (AOR, 1.32; 95% CI, 1.14-1.54). In addition, use of PPI without clopidogrel was not associated with death or rehospitalization for ACS among patients not taking clopidogrel after hospital discharge (n = 6450) (AOR, 0.98; 95% CI, 0.85-1.13).
Conclusion Concomitant use of clopidogrel and PPI after hospital discharge for ACS was associated with an increased risk of adverse outcomes than use of clopidogrel without PPI, suggesting that use of PPI may be associated with attenuation of benefits of clopidogrel after ACS.
Author Affiliations: Denver VA Medical Center, Denver, Colorado (Drs Ho, Maddox, and Rumsfeld); University of Colorado Health Sciences Center, Denver (Drs Ho, Maddox, and Rumsfeld); VA Puget Sound Health Care System, Seattle, Washington (Ms Wang and Dr Fihn); VA Central Office, Washington, DC (Drs Fihn and Jesse); Richmond VA Medical Center, Richmond, Virginia (Dr Jesse); and Duke Clinical Research Institute, Durham, North Carolina (Dr Peterson).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
Young Kwang Chae and Jongoh Kim
JAMA. 2009;302(1):29.
EXTRACT
| FULL TEXT
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
Verena Schneider-Lindner, Kristian B. Filion, and James M. Brophy
JAMA. 2009;302(1):29-30.
EXTRACT
| FULL TEXT
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
Habib A. Dakik and Kassem Barada
JAMA. 2009;302(1):30.
EXTRACT
| FULL TEXT
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
Stephen Hayes
JAMA. 2009;302(1):30-31.
EXTRACT
| FULL TEXT
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel—Reply
P. Michael Ho, John S. Rumsfeld, and Li Wang
JAMA. 2009;302(1):31.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Review of recent evidence: Potential interaction between clopidogrel and proton pump inhibitors
Last and Sheehan
Am J Health Syst Pharm 2009;66:2117-2122.
ABSTRACT
| FULL TEXT
Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer: A Dose-Escalation Study
Gladding et al.
J Am Coll Cardiol Intv 2009;2:1095-1101.
ABSTRACT
| FULL TEXT
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome.
Giugliano and Braunwald
J Am Coll Cardiol 2009;54:1544-1555.
FULL TEXT
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Nikolsky et al.
J Am Coll Cardiol 2009;54:1293-1302.
ABSTRACT
| FULL TEXT
Clopidogrel plus aspirin in atrial fibrillation.
Pisters et al.
NEJM 2009;361:1312-1313.
FULL TEXT
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Cuisset et al.
J Am Coll Cardiol 2009;54:1149-1153.
ABSTRACT
| FULL TEXT
Cardiovascular Effects of Noncardiovascular Drugs
Raj et al.
Circulation 2009;120:1123-1132.
FULL TEXT
Antithrombotics in acute coronary syndromes.
Bonaca et al.
J Am Coll Cardiol 2009;54:969-984.
ABSTRACT
| FULL TEXT
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Shuldiner et al.
JAMA 2009;302:849-857.
ABSTRACT
| FULL TEXT
Personalized medicine and antiplatelet therapy: ready for prime time?
Verstuyft et al.
Eur Heart J 2009;30:1943-1963.
FULL TEXT
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
Chae and Kim
JAMA 2009;302:29-29.
FULL TEXT
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
Dakik and Barada
JAMA 2009;302:30-30.
FULL TEXT
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
Schneider-Lindner et al.
JAMA 2009;302:29-30.
FULL TEXT
Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
Hayes
JAMA 2009;302:30-31.
FULL TEXT
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Norgard et al.
The Annals of Pharmacotherapy 2009;43:1266-1274.
ABSTRACT
| FULL TEXT
Interaction between clopidogrel and proton pump inhibitors
Juurlink et al.
CMAJ 2009;180:1229-1229.
FULL TEXT
Update on dual antiplatelet therapy for percutaneous coronary intervention
Prasad and Holmes
Heart 2009;95:861-865.
FULL TEXT
More on proton pump inhibitors
Sadler and Poullis
BMJ 2009;338:b1931-b1931.
FULL TEXT
Authors' reply
Chua and Ignaszewski
BMJ 2009;338:b2006-b2006.
FULL TEXT
Clopidogrel and the Concept of High-Risk Pharmacokinetics
Roden and Stein
Circulation 2009;119:2127-2130.
FULL TEXT
Coronary Stents and Chronic Anticoagulation
Sourgounis et al.
Circulation 2009;119:1682-1688.
FULL TEXT
Proton-Pump Inhibitors and Clopidogrel: Bad Company?
JWatch Oncology and Hematology 2009;2009:5-5.
FULL TEXT
Clopidogrel and Proton-Pump Inhibitors
JWatch General 2009;2009:1-1.
FULL TEXT
All you need to read in the other general journals
BMJ 2009;338:b963-b963.
FULL TEXT
Proton-Pump Inhibitors and Clopidogrel: Bad Company?
JWatch Gastroenterology 2009;2009:1-1.
FULL TEXT
Proton Pump Inhibitors and Clopidogrel: Bad Company?
Journal Watch Cardiology 2009;2009:1-1.
FULL TEXT
|
